Biocon Limited

Company Profile

Biocon Limited had its IPO on under the ticker symbol BIOCON.

The company operates in the Healthcare sector and Biotechnology industry. Biocon Limited has a staff strength of 16,545 employees.

Stock update

Shares of Biocon Limited opened at ₹277.3 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹265.55 - ₹277.3, and closed at ₹267.3.

This is a -3.29% slip from the previous day's closing price.

A total volume of 5,318,523 shares were traded at the close of the day’s session.

In the last one week, shares of Biocon Limited have increased by +2.28%.

Biocon Limited's Key Ratios

Biocon Limited has a market cap of ₹319.96 billion, indicating a price to book ratio of 3.3875 and a price to sales ratio of 3.656.

In the last 12-months Biocon Limited’s revenue was ₹124.57 billion with a gross profit of ₹54.66 billion and an EBITDA of ₹29.05 billion. The EBITDA ratio measures Biocon Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Biocon Limited’s operating margin was 13.96% while its return on assets stood at 2.7% with a return of equity of 4.02%.

In Q2, Biocon Limited’s quarterly earnings growth was a negative -29.8% while revenue growth was a positive 60%.

Biocon Limited’s PE and PEG Ratio

Forward PE

0

Trailing PE

76.5805

PEG

Its diluted EPS in the last 12-months stands at ₹3.48 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Biocon Limited’s profitability.

Biocon Limited stock is trading at a EV to sales ratio of 3.8294 and a EV to EBITDA ratio of 17.1914. Its price to sales ratio in the trailing 12-months stood at 3.656.

Biocon Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0.56% and a payout ratio of 43.07%.

Balance sheet and cash flow metrics

Total Assets

₹520.43 billion

Total Liabilities

₹85.11 billion

Operating Cash Flow

₹0

Capital Expenditure

₹0

Dividend Payout Ratio

43.07%

Biocon Limited ended 2024 with ₹520.43 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹520.43 billion while shareholder equity stood at ₹178.67 billion.

Biocon Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹85.11 billion in other current liabilities, 6003000000.00 in common stock, ₹172.67 billion in retained earnings and ₹161.36 billion in goodwill. Its cash balance stood at ₹13.24 billion and cash and short-term investments were ₹38.59 billion. The company’s total short-term debt was ₹0 while long-term debt stood at ₹152.91 billion.

Biocon Limited’s total current assets stands at ₹123.34 billion while long-term investments were ₹0 and short-term investments were ₹14.59 billion. Its net receivables were ₹35.73 billion compared to accounts payable of ₹39.83 billion and inventory worth ₹42.44 billion.

In 2024, Biocon Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Biocon Limited paid ₹0.43 in dividends in 2024.

Other key metrics

Current Trading Price

₹267.3

52-Week High

₹307.2149

52-Week Low

₹190.4932

Analyst Target Price

₹

Biocon Limited stock is currently trading at ₹267.3 per share. It touched a 52-week high of ₹307.2149 and a 52-week low of ₹307.2149. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹259.91 and 200-day moving average was ₹245.51 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 6290.3% of the company’s stock are held by insiders while 1668.9% are held by institutions.